Spots Global Cancer Trial Database for Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
Official Title: Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
Study ID: NCT04501939
Conditions
Study Description
Brief Summary: Single center, open-label, phase 2 study to determine the efficacy of cirmtuzumab consolidation in patients with measurable disease on venetoclax.
Detailed Description: This is a phase 2 study to test whether cirmtuzumab in combination with venetoclax given as consolidation therapy can decrease the number of cancer cells that may be left in the bone marrow or in the blood in patients who have been treated with venetoclax for at least one year. Consolidation therapy is given after initial cancer treatment to further reduce the number of cancer cells that may be left in the body. Cirmtuzumab, a monoclonal antibody that inhibits receptor tyrosine kinase like orphan receptor (ROR1) signaling and stemness, may be effective in reducing the risk of disease progression in patients with detectable minimal residual disease (MRD) after treatment with venetoclax.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCSD Koman Family Outpatient Pavilion, San Diego, California, United States
Contact Details
Name: Benjamin M Heyman, MD
Affiliation: University of California, San Diego
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
